PHILADELPHIA, Nov. 1, 2005 (PRIMEZONE) -- Kibow Biotech Inc. is pleased to announce its continued exhibit participation at the American Society of Nephrology's (ASN) 38th annual Meeting & Scientific Exposition/Renal Week being held November 8-13, 2005 at the Pennsylvania Convention Center in Philadelphia. Although various continuing medical education courses, scientific seminars and meetings will be scheduled during all six days, the exhibits will be organized only for three days - Nov. 10- 12, 2005. This ASN meeting is also an event which draws thousands of nephrology and related healthcare professionals from all around the globe.
Kibow Biotech Inc. is an eight-year-old, developing-stage biotechnology company having its operations at the Science Center in close proximity to Drexel and the University of Pennsylvania. The company's mission is dedicated to finding a simple, convenient and cost-effective worldwide solution for patients suffering kidney failure. The company's first generation product called Kibow Biotics(R), an orally consumable, enterically coated Gel Cap product formulation is composed of food grade microbes (Probiotics) which utilizes or 'mops up' the uremic toxins diffusing into the bowel as a consequence of increased levels of these toxins in the blood. It is targeted to help augment or maintain kidney function both for Chronic Kidney Disease (CKD) patients (pre-dialysis) and End Stage Renal Disease (ESRD) patients.
The company is seeking needed funds to initially establish the "proof of concept" of their platform technology. Kibow is also seeking additional funding to conduct multisite human clinical trials in various countries including the United States, Canada, Japan, Mexico and India, to obtain the efficacy of their Kibow Biotics(R) first-generation probiotics product formulation.
Forward-looking Statement Disclaimer: Kibow Biotech company's Web site contains both historical information and also contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are not guarantees of future performance. By their nature, forward-looking statements involve numerous assumptions, known and unknown risks, uncertainties and other factors that may cause the actual results or performance of the Company to be materially different from such statements or from any future results or performance implied thereby. Factors which could cause the Company's results or performance to differ from current expectations include, but are not limited to, timely regulatory approval of the Company's products; the ability to comply with regulatory requirements applicable to the manufacture and marketing of the Company's products; the Company's ability to obtain and enforce effective patents; the non-infringement of third party patents or proprietary rights by the Company and its products; the establishment and maintenance of strategic collaborative and commercial relationships; The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.